#United States #New York #kidney disease #Tempus AI #Renalytix

Renalytix and Tempus Join Forces to Combat Diabetic Kidney Disease

Renalytix plc has officially announced a significant partnership with Tempus AI, Inc., aimed at enhancing the risk assessment process for diabetic kidney disease. The collaboration centers around the kidneyintelX.dkd test, which has already gained FDA approval and is eligible for Medicare reimbursement. This initiative seeks to enhance clinical outcomes for type 2 diabetes patients suffering from chronic kidney disease (CKD) across the United States—a condition affecting about 15 million individuals in the country alone.

Expansion of Access to KidneyintelX.dkd

The partnership marks the introduction of kidneyintelX.dkd to Tempus' robust portfolio of diagnostics, specifically tailored for chronic kidney disease assessments. This cutting-edge test informs healthcare providers about a patient's risk of progressive kidney function decline, categorizing patients into high, moderate, or low-risk groups. Such stratification is not only crucial for early intervention but also plays a significant role in managing the overall health of diabetic patients, thereby reducing complications and healthcare costs.

James McCullough, CEO of Renalytix, expressed his enthusiasm about the collaboration, noting that Tempus’s extensive platform would significantly enhance the accessibility of precision medicine testing. McCullough stated, "The unique Tempus platform, with its broad clinical reach, will allow us to significantly expand patient and clinician access to advance kidneyintelX.dkd precision medicine testing..."

Leveraging AI for Patient-Centric Care

Tempus CEO Ryan Fukushima echoed this sentiment, highlighting the shared mission of both companies to innovate within artificial intelligence-enabled diagnostics. He noted that this partnership not only expands their reach within the diabetes and chronic kidney disease sectors but also aims to enhance clinical decision-making through actionable insights derived from advanced data analytics.

This collaboration will facilitate the integration of kidneyintelX.dkd testing into existing clinical workflows within various US health systems, allowing healthcare providers to easily order tests for eligible patients. The results will be processed in Renalytix laboratories, and subsequently, the findings will be reported electronically to clinicians and available in patient portals when applicable.

Timeliness and Impact on Patient Management

One of the primary advantages of kidneyintelX.dkd lies in its ability to provide insights that can lead to timely alterations in patient management strategies. By identifying risk levels early on, healthcare providers can initiate appropriate interventions, thereby potentially slowing the progression of kidney disease and improving key quality metrics in diabetes care.

The dire statistics surrounding chronic kidney disease (CKD) amplify the urgency of this partnership. Globally, CKD poses a serious public health crisis involving approximately 850 million people, with 90% of those affected unaware of their condition. In the United States alone, Medicare incurs an annual expenditure exceeding $130 billion for the care of individuals suffering from kidney disease.

About Renalytix

Renalytix is at the forefront of artificial intelligence-enabled diagnostics, dedicated to improving kidney disease management through advanced technological solutions. With the integration of kidneyintelX.dkd into clinical practice, the aim is to enhance patient outcomes significantly. For additional insights into Renalytix and the kidneyintelX.dkd test, visit their official website at renalytix.com.

As healthcare systems increasingly embrace technology to optimize patient care, the joint effort of Renalytix and Tempus underscores the potential of AI in transforming the landscape of chronic disease treatment. This partnership not only promises timely intervention for millions but also paves the way for a deeper understanding of kidney health in diabetic patients.